WA
MRNA icon

Winfield Associates’s Moderna MRNA Stock Holding History

Winfield Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,085
Closed -$276K – 158
2021
Q4 		$276K Sell
1,085
-3,725
-77% -$1.09M 0.09% 134
2021
Q3 		$1.85M Buy
4,810
+885
+23% +$326K 0.68% 43
2021
Q2 		$922K Hold
3,925
– – 0.34% 66
2021
Q1 		$514K Buy
3,925
+100
+3% +$14.5K 0.21% 91
2020
Q4 		$400K Hold
3,825
– – 0.17% 95
2020
Q3 		$271K Buy
+3,825
New +$267K 0.13% 103

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Winfield Associates's MRNA Position: Q1 2022 in Review

Winfield Associates sold out of Moderna (MRNA) in Q1 2022, closing a stake of 1,085 shares — an estimated $276K sold.

Winfield Associates first reported a position in MRNA in Q3 2020 and held it in 6 quarters. The position peaked at $1.85M in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Winfield Associates reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Winfield Associates sold 1,085 Moderna shares in Q1 2022, an estimated $276K.
  • Winfield Associates first reported a position in Moderna in Q3 2020 and held it in 6 quarters.
  • Winfield Associates's Moderna position peaked at $1.85M in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Winfield Associates's 13F filing for Q1 2022, filed 5 Apr 2022.